scholarly journals Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association

Author(s):  
Ferhaan Ahmad ◽  
Elizabeth M. McNally ◽  
Michael J. Ackerman ◽  
Linda C. Baty ◽  
Sharlene M. Day ◽  
...  

Cardiovascular genetics is a rapidly evolving subspecialty within cardiovascular medicine, and its growth is attributed to advances in genome sequencing and genetic testing and the expanding understanding of the genetic basis of multiple cardiac conditions, including arrhythmias (channelopathies), heart failure (cardiomyopathies), lipid disorders, cardiac complications of neuromuscular conditions, and vascular disease, including aortopathies. There have also been great advances in clinical diagnostic methods, as well as in therapies to ameliorate symptoms, slow progression of disease, and mitigate the risk of adverse outcomes. Emerging challenges include interpretation of genetic test results and the evaluation, counseling, and management of genetically at-risk family members who have inherited pathogenic variants but do not yet manifest disease. With these advances and challenges, there is a need for specialized programs combining both cardiovascular medicine and genetics expertise. The integration of clinical cardiovascular findings, including those obtained from physical examination, imaging, and functional assessment, with genetic information allows for improved diagnosis, prognostication, and cascade family testing to identify and to manage risk, and in some cases to provide genotype-specific therapy. This emerging subspecialty may ultimately require a new cardiovascular subspecialist, the genetic cardiologist, equipped with these combined skills, to permit interpretation of genetic variation within the context of phenotype and to extend the utility of genetic testing. This scientific statement outlines current best practices for delivering cardiovascular genetic evaluation and care in both the pediatric and the adult settings, with a focus on team member expertise and conditions that most benefit from genetic evaluation.

Author(s):  
Kiran Musunuru ◽  
Ray E. Hershberger ◽  
Sharlene M. Day ◽  
N. Jennifer Klinedinst ◽  
Andrew P. Landstrom ◽  
...  

Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families. This statement summarizes current best practices with respect to genetic testing and its implications for the management of inherited cardiovascular diseases.


2018 ◽  
Vol 104 (5) ◽  
pp. 451-455 ◽  
Author(s):  
Scott A Cameron ◽  
Michael Carr ◽  
Elfriede Pahl ◽  
Nicole DeMarais ◽  
Stanford T Shulman ◽  
...  

ObjectiveWe aimed to compare the severity of coronary artery abnormalities in Kawasaki disease between infants and older children.MethodsWe retrospectively reviewed and compared coronary artery dilation and aneurysm severity in infants <1 year of age with Kawasaki disease at our centre over a 10-year period with that observed in children ≥1 year of age in the Pediatric Heart Network Trial of Pulse Steroid Therapy in Kawasaki Disease. Coronary artery abnormalities were defined by z-scores according to American Heart Association guidelines.ResultsOf the 93 infants identified during the study period, 80 were treated with intravenous gamma globulin within the first 10 days of illness and were included for comparison to 170 children ≥1 year of age treated in the same time frame from the Pediatric Heart Network public database. The mean maximum z-score was significantly higher in infants compared with older children (3.37 vs 2.07, p<0.001). A higher incidence of medium and giant aneurysms was observed in infants compared with children ≥1 year of age (11% vs 3% for medium aneurysms, p=0.015; 8% vs <1% for giant aneurysms, p=0.005).ConclusionsInfants with Kawasaki disease have more severe coronary artery dilation compared with older children, and a higher prevalence of medium and giant aneurysms. Because adverse outcomes are closely linked to the maximal coronary artery diameter in Kawasaki disease, patients diagnosed as infants require very close long-term monitoring for cardiac complications.


2020 ◽  
Vol 1 (3) ◽  
pp. 16-26
Author(s):  
M. S. Litvinova ◽  
L. A. Khaisheva ◽  
S. V. Shlyk

The concept of resistant arterial hypertension was introduced many years ago and confirmed in the updated scientific statement of the American Heart Association (AHA) 2018 and the latest recommendations of the European Society of Cardiology (ESC) 2018. Special attention to this group of patients is due to the high risk of adverse outcomes compared with controlled hypertension. In this review, we want to highlight not only the difficulties in identifying, assessing and optimizing therapy for patients with RH, but to a greater extent focus on the main mechanisms of the formation of true resistance, their identification and the search for the optimal path of action.


Author(s):  
Andrew P. Landstrom ◽  
Jeffrey J. Kim ◽  
Bruce D. Gelb ◽  
Benjamin M. Helm ◽  
Prince J. Kannankeril ◽  
...  

Genetic diseases that affect the cardiovascular system are relatively common and include cardiac channelopathies, cardiomyopathies, aortopathies, hypercholesterolemias, and structural diseases of the heart and great vessels. The rapidly expanding availability of clinical genetic testing leverages decades of research into the genetic origins of these diseases, helping inform diagnosis, clinical management, and prognosis. Although a number of guidelines and statements detail best practices for cardiovascular genetic testing, there is a paucity of pediatric-focused statements addressing the unique challenges in testing in this vulnerable population. In this scientific statement, we seek to coalesce the existing literature around the use of genetic testing for cardiovascular disease in infants, children, and adolescents.


2016 ◽  
Vol 9 (5) ◽  
pp. 448-467 ◽  
Author(s):  
Seema Mital ◽  
Kiran Musunuru ◽  
Vidu Garg ◽  
Mark W. Russell ◽  
David E. Lanfear ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document